Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib ± Toripalimab in Advanced Solid Tumors
CTR20191865Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, toripalimab in Nonhematologic neoplasms, neuroendocrine carcinoma (NEC), cholangiocarcinoma (CCA), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by HUTCHMED. Started Sep 2019; status: completed.
02
Drugs
surufatinibtoripalimab
03
Conditions
Nonhematologic neoplasmsneuroendocrine carcinoma (NEC)cholangiocarcinoma (CCA)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20191865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191865.